Peptide Co-Agonists for Combined Activation of the APJ and GLP-1 Receptors with Insulinotropic and Satiety Actions Show Potential for Alleviation of Metabolic Dysfunction in Type 2 Diabetes

Peptide Co-Agonists for Combined Activation of the APJ and GLP-1 Receptors with Insulinotropic and Satiety Actions Show Potential for Alleviation of Metabolic Dysfunction in Type 2 Diabetes

Stable analogues of the adipokine apelin-13 have shown promising therapeutic potential via APJ receptor activation in isolated β-cells and in animal models of obesity-related diabetes. Incretin mimetics such as exenatide that bind to GLP-1 receptors are well-established Type 2 diabetes treatment opt...

Full description

Saved in:
Bibliographic Details
Main Authors: Finbarr O’Harte, Vadivel Parthsarathy, Sarah Craig, Ethan Palmer, Nigel Irwin
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Medical Sciences Forum
Subjects:
apelin
incretin action
diabetes therapy
insulin secretion
hybrid peptides
Online Access:https://www.mdpi.com/2673-9992/23/1/1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items